

PRESS RELEASE

Grenchen, March 9, 2016

Thommen guided surgery – StecoGuide double sleeves are now available for Thommen VECTOdrill[™]! Perform guided implant surgery with a proven and precise drill protocol

Thommen Medical AG (Grenchen, Switzerland), together with Steco-System-Technik (Hamburg, Germany), is launching the StecoGuide double sleeve for Thommen Implants. The most important drilling sequences, including pilot drilling, are now guided while utilizing the existing drill protocol.

The StecoGuide double sleeve system has been adapted to the design of the Thommen VECTOdrill and now enables sequential guided drilling of the most important drilling sequences. The system consists of an outer sleeve and two inner sleeves that can be perfectly integrated into the existing drill protocol. Depth control is carried out manually by means of the laser marking of the VECTOdrill. The blue StecoGuide sleeves for Thommen Implants are currently integrated into common planning systems (e.g. 3Shape ImplantStudio, Swissmeda SMOP).

StecoGuide double sleeves are renowned as a simple and effective universal guided drilling system, independent of manufacturer. StecoGuide double sleeves for Thommen implants are available directly from Steco (phone +49 40 5577810; info@steco.de) or local distributors.

Contact

Thommen Medical AG
Neckarsulmstrasse 28
CH-2540 Grenchen
Tel. +41 61 965 90 20
Fax +41 61 965 90 21
presse@thommenmedical.com
www.thommenmedical.com



The press release is also available online: http://www.thommenmedical.com/en/company/media/press-releases.html

About Thommen Medical

Thommen Medical develops, manufactures and sells high-quality products for dental implantology, mainly the Thommen Implant System and biomaterials. Swiss



precision, innovation, and functional design form the basis for all of the company's products. Thommen Medical's headquarters and and private manufacturing facility is located in Grenchen, Switzerland. Thommen Medical has subsidiaries in Switzerland, Germany, Austria, United States and Canada, and is represented by distribution partners in most other major markets of Europe, Asia and the Middle East. It is currently a privately held company, with two private investor groups and Novartis being the majority stockholders.